Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVersys AGXSWX:BIOV -1.59%4 Equity-to-Asset is 0.66 as of Dec. 2025, which is 38% above its 10-year median of 0.48. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,416 Biotechnology companies, BioVersys AG ranks worse than 52.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioVersys AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF59.81 Mil. BioVersys AG's Total Assets for the quarter that ended in Dec. 2025 was CHF90.64 Mil.
Therefore, BioVersys AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.66.
The historical rank and industry rank for BioVersys AG's Equity-to-Asset or its related term are showing as below:
XSWX:BIOV'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31 Med: 0.48 Max: 0.66
Current: 0.66
During the past 2 years, the highest Equity to Asset Ratio of BioVersys AG was 0.66. The lowest was 0.31. And the median was 0.48.
XSWX:BIOV's Equity-to-Asset is ranked worse than 52.05% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs XSWX:BIOV: 0.66
BioVersys AG (XSWX:BIOV) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioVersys AG Equity-to-Asset Related Terms
BioVersys AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Equity-to-Asset Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
0.31
0.66
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Equity-to-Asset
0.00
0.31
0.74
0.66
XSWX:BIOV vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, BioVersys AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioVersys AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a Equity-to-Asset of 0.66 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioVersys AG and its competitors. This is 38% above median its historical median of 0.48. Over the past decade, BioVersys AG's Equity-to-Asset has ranged from 0.31 to 0.66. According to the industry distribution chart, BioVersys AG ranks #737 out of 1416 companies in the Biotechnology industry, placing it in the top 52%.
Is BioVersys AG's Equity-to-Asset too high?
BioVersys AG's current Equity-to-Asset of 0.66 is 38% above median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 0.66. The Biotechnology industry median Equity-to-Asset is 0.68. BioVersys AG's value of 0.66 is 2.9% below this industry median. Based on the distribution chart, BioVersys AG ranks #737 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #737 out of 1416 companies for Equity-to-Asset. This places BioVersys AG in the lower half of its industry. The industry median Equity-to-Asset is 0.68. BioVersys AG's value of 0.66 is 2.9% below this benchmark. Historically, BioVersys AG's own Equity-to-Asset has ranged from 0.31 to 0.66 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 0.68, BioVersys AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVersys AG's current Equity-to-Asset of 0.66 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current Equity-to-Asset is 0.66, which is 38% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Equity-to-Asset of 0.66. The current Equity-to-Asset is 0.66, which is 38% above median its 10-year median of 0.48 and 2.9% below the Biotechnology industry median of 0.68. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Equity-to-Asset is 0.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
